A 64-year-old woman with primary hyperparathyroidism

JAMA

Volumn 293, Issue 14, 2005, Pages 1772-1779

  Strewler, Gordon J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE;

ADULT; ANAMNESIS; ARTICLE; BLOOD TESTIS BARRIER; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CASE REPORT; DISEASE SEVERITY; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; HYPERCALCEMIA; LABORATORY TEST; MEDICAL SPECIALIST; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATIENT; PATIENT REFERRAL; PHYSICAL EXAMINATION; PHYSICIAN; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SPINE; SURGEON; SURGICAL TECHNIQUE; SYMPTOM; THYROID GLAND; TREATMENT INDICATION; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; HYPERPARATHYROIDISM; MIDDLE AGED; PATHOPHYSIOLOGY;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; MIDDLE AGED; PARATHYROIDECTOMY;

EID: 16444364269     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.14.1772     Document Type: Article

References (84)

1. Boonstra CE, Jackson CE. Serum calcium survey for hyperparathyroidism: results in 50,000 clinic patients. Am J Clin Pathol. 1971;55:523-526.
2. Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med. 1998;104:115-122.
3. Heath H III, Hodgson SF, Kennedy MA. Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302:189-193.
4. Brown EM. The pathophysiology of primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N24-N29.
5. Imanishi Y, Hosokawa Y, Yoshimoto K, et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest. 2001;107:1093-1102.
6. Parfitt AM. Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. Bone. 2003;33:259-263.
7. Kao PC, van Heerden JA, Grant CS, Klee CC, Khosla S. Clinical performance of parathyroid hormone immunometric assays. Mayo Clin Proc. 1992;67: 637-645.
8. Silverberg SJ, Gao P, Brown I, LoGerfo P, Cantor TL, Bilezikian JP. Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:4725-4730.
9. Bilezikian JP, Silverberg SJ. Asymptomatic primary hyperparathyroidism. N Engl J Med. 2004;350:1746-1751.
10. Fuleihan G el-H. Familial benign hypocalciuric hypercalcemia. J Bone Miner Res. 2002;17(suppl 2):N51-N56.
11. Brown EM. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol Metab Clin North Am. 2000;29:503-522.
12. Marx SJ, Simonds WF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002; 17(suppl 2):N37-N43.
13. Awad SS, Miskulin J, Thompson N. Parathyroid adenomas versus four-gland hyperplasia as the cause of primary hyperparathyroidism in patients with prolonged lithium therapy. World J Surg. 2003;27:486-488.
14. Haden ST, Stoll AL, McCormick S, Scott J, Fuleihan G el-H. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab. 1997;82:2844-2848.
15. Bendz H, Sjodin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy - a cross-sectional study and the effect of lithium withdrawal. J Intern Med. 1996;240:357-365.
16. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-1255.
17. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:723-728.
18. Miller PD, Bilezikian JP. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N98-N102.
19. Dempster DW, Parisien M, Silverberg SJ, et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab. 1999;84:1562-1566.
20. Parisien M, Mellish RWE, Silverberg SJ, et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res. 1992;7:913-919.
21. Eriksen EF, Mosekilde L, Melsen F. Trabecular bone remodeling and bone balance in hyperthyroidism. Bone. 1985;6:421-428.
22. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321:598-602.
23. Khosla S, Melton LJ III, Wermers RA, Crowson CS, O'Fallon W, Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14:1700-1707.
24. Wilson RJ, Rao DS, Ellis B, Kleerekoper M, Parfitt AM. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med. 1988;109:959-962.
25. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
26. Silverberg SJ. Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N117-N125.
27. Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy: a case-control study. Ann Surg. 1995;222:402-412.
28. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 1998;22:513-518.
29. Talpos GB, Bone HG III, Kleerekoper M, et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery. 2000;128:1013-1020.
30. Lundgren E, Lind L, Palmer M, Jakobsson S, Ljunghall S, Rastad J. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery. 2001;130:978-985.
31. Hedback C, Oden A. Increased risk of death from primary hyperparathyroid-ism - an update. Eur J Clin Invest. 1998;28:271-276.
32. Walgenbach S, Hommel C, Junginger T. Outcome after surgery for primary hyperparathyroidism: ten-year prospective follow-up study. World J Surg. 2000; 24:564-569.
33. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe - nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res. 2002;17(suppl 2):N68-N74.
34. Nainby-Luxmoore JC, Langford HG, Nelson NC, Watson RL, Barnes TY. A case-comparison study of hypertension and hyperparathyroidism. J Clin Endocrinol Metab. 1982;55:303-306.
35. Bradley EL III, Wells JO. Primary hyperparathyroidism and hypertension. Am Surg. 1983;49:569-570.
36. Stefenelli T, Mayr H, Bergler-Klein J, Globits S, Woloszczuk W, Niederle B. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med. 1993;95:197-202.
37. Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab. 1997;82:106-112.
38. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int. 2001;60:472-479.
39. Bostrom K, Demer LL. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryot Gene Expr. 2000;10:151-158.
40. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism: 10-year prospective study. Mayo Clin Proc. 1981;56:473-478.
41. Hemmer S, Wasenius VM, Haglund C, et al. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol. 2001;158:1355-1362.
42. Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996;81:1736-1739.
43. Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet. 1997;16:375-378.
44. Carling T, Correa P, Hessman O, et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab. 1998;83:2960-2963.
45. Farnebo F, Teh ST, Kytola S, et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab. 1998;83:2627-2630.
46. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32: 676-680.
47. Parfitt AM, Wang Q, Palnitkar S. Rates of cell proliferation in adenomatous, suppressed, and normal parathyroid tissue: implications for pathogenesis. J Clin Endocrinol Metab. 1998;83:863-869.
48. Parfitt AM. Parathyroid growth: normal and abnormal. In: Bilezikian JP, Marcus R, Levine MA, eds. The Parathyroids: Basic and Clinical Concepts. San Diego, Calif: Academic Press: 2001:293-329.
49. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab. 1983;56:572-581.
50. Brown EM, MacLeod PJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81:239-297.
51. Strewler GJ. Medical approaches to primary hyperparathyroidism. Endocrinol Metab Clin North Am. 2000;29:523-539.
52. Marcus R, Madvig P, Crim M, Pont A, Kosek J. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med. 1984;100:633-640.
53. Selby PL, Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med. 1986;314: 1481-1485.
54. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized, controlled trial. Ann Intern Med. 1996; 125:360-368.
55. Rossouw JE, Anderson CL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
56. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy CR. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab. 1993;77:1067-1071.
57. Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:581-587.
58. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab. 2002;87:4482-4489.
59. Rossini M, Gatti D, Isaia C, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001;16:113-119.
60. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319-3325.
61. Antoniucci DM, Shoback D. Calcimimetics in the treatment of primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N141-N145.
62. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A. 1998;95:4040-4045.
63. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. 2000;57:50-58.
64. Wada M, Nagano N. Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transplant. 2003;18(suppl 3):iii13-iii17.
65. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14:575-583.
66. Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nephrol. 2003;18:1206-1210.
67. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135-141.
68. Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol. 2000;11:903-911.
69. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab. doi:10.210/jc2004-1772. Published online January 11, 2005. Accessed March 16, 2005.
70. Proceedings of the NIH Consensus Development Conference on diagnosis and management of asymptomatic primary hyperparathyroidism, Bethesda, Maryland, October 29-31, 1990. J Bone Miner Res. 1991;6(suppl 2):S1-S166.
71. Sosa JA, Powe NR, Levine MA, Udelsman R, Zeiger MA. Profile of a clinical practice: thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. J Clin Endocrinol Metab. 1998;83:2658-2665.
72. Udelsman R. Surgery in primary hyperparathyroidism: the patient without previous neck surgery. J Bone Miner Res. 2002;17(suppl 2):N126-N132.
73. Sosa JA, Udelsman R. Minimally invasive parathyroidectomy. Surg Oncol. 2003; 12:125-134.
74. Civelek AC, Ozalp E, Donovan P, Udelsman R. Prospective evaluation of delayed technetium-99m sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism. Surgery. 2002;131:149-157.
75. Denham DW, Norman J. Cost-effectiveness of preoperative sestamibi scan for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure. J Am Coll Surg. 1998;186:293-305.
76. Irvin GL III, Dembrow VD, Prudhomme DL. Clinical usefulness of an intraoperative "quick parathyroid hormone" assay. Surgery. 1993;114:1019-1022.
77. Haciyanli M, Lal G, Morita E, Dun QY, Kebebew E, Clark OH. Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma. J Am Coll Surg. 2003;197:739-746.
78. Garner SC, Leight GS Jr. Initial experience with intraoperative PTH determinations in the surgical management of 130 consecutive cases of primary hyperparathyroidism. Surgery. 1999;126:1132-1137.
79. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002;235:665-670.
80. Deaconson TF, Wilson SD, Lemann J Jr. The effect of parathyroidectomy on the recurrence of nephrotithiasis. Surgery. 1987;102:910-913.
81. Mollerup CL, Vestergaard P, Frokjaer VG, Mosekilde L, Christiansen P, Blichert-Toft M. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ. 2002;325: 807.
82. Bilezikian JP, Potts JT Jr, Fuleihan G, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 2002;87:5353-5361.
83. Proceedings of the NIDDK Workshop program. Asymptomatic primary hyperparathyroidism: a perspective for the 21st century, Bethesda, Maryland, USA, April 8-9, 2002. J Bone Miner Res. 2003;17(suppl 2):N1-N162.
84. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med. 1997;126: 497-504.